Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2236473 | 0.93 | OPRM1 (0.46) | OPRM1KDM4EGAALMNACHRM2 | |
| SCHEMBL1935385 | 0.87 | S1PR1 (0.45) | OPRM1KDM4EGAALMNACHRM2 | |
| SCHEMBL2238150 | 0.87 | MCHR1 (0.50) | OPRM1KDM4EALDH1A1 | |
| SCHEMBL2240263 | 0.87 | OPRM1 (0.48) | OPRM1KDM4EGAALMNACHRM2 | |
| SCHEMBL2237331 | 0.86 | ALDH1A1 (0.55) | OPRM1KDM4EALDH1A1 | |
| SCHEMBL2314469 | 0.85 | OPRM1 (0.46) | OPRM1KDM4EGAALMNACHRM2 | |
| SCHEMBL2237887 | 0.85 | S1PR1 (0.45) | OPRM1KDM4EGAALMNAMEN1 | |
| SCHEMBL2237167 | 0.84 | OPRM1 (0.48) | OPRM1KDM4EGAALMNACHRM2 | |
| SCHEMBL2239987 | 0.84 | OPRM1 (0.48) | OPRM1KDM4EGAALMNACHRM2 | |
| SCHEMBL2234975 | 0.82 | OPRM1 (0.44) | OPRM1KDM4EGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | OPRM1 442/4885KDM4E 2968/4885GAA 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.